Steroid receptors and other prognostic factors in primary breast cancer.
Steroid receptors and other prognostic factors in primary breast cancer.
复制标题
DOI：
10.5555/uri:pii:0093775488901066
复制
发表时间：
1988-04
影响因子：
4
通讯作者：
G. Clark;W. McGuire
中科院分区：
文献类型：
--
作者：
G. Clark;W. McGuire
对已发表的预后因素研究的回顾和更新支持以下结论：肿瘤累及腋窝淋巴结的数量仍然是原发性乳腺癌女性最重要的预后因素。在I期疾病中，雌激素受体（ER）的缺乏似乎是预测早期复发和较差生存率的最重要因素。在II期乳腺癌中，孕激素受体（PgR）含量在预测无病生存和总生存方面似乎优于ER含量。通过胸苷标记或流式细胞术（FCM）测量增殖活性（S期DNA）和通过FCM测量非整倍体也提供预后信息。非整倍体肿瘤或高S期二倍体肿瘤患者复发风险增加。癌基因的扩增，特别是HER-2/neu，可以提供额外的预后信息与其他既定的预后因素相结合。
A review and update of published studies on prognostic factors support the following conclusions: The number of axillary lymph nodes involved with tumor remains the most important prognostic factor for women with primary breast cancer. In stage I disease, the lack of estrogen receptor (ER) seems to be the most important factor for predicting earlier recurrence and poorer survival. In stage II breast cancer, progesterone receptor (PgR) content appears to be better than ER content in predicting disease-free and overall survival. Measurement of proliferative activity (S-phase DNA) by thymidine labeling or flow cytometry (FCM) and of aneuploidy by FCM also provides prognostic information. Patients with aneuploid tumors, or with high S-phase diploid tumors, are at increased risk for relapse. Amplification of oncogenes, particularly HER-2/neu, may provide additional prognostic information in combination with other established prognostic factors.